TRIAL DATA
Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer — Scientific Reports
A phase 2 study tested alpelisib (a PI3K inhibitor) combined with capecitabine in 26 patients with PIK3CA-mutant metastatic colorectal cancer who had progressed after standard chemotherapy. The trial was conducted across nine institutions. Median progression-free survival was 3.5 months and overall survival was 8.8 months, with partial responses observed in two patients and disease control achieved in more than half of the cohort. Clinical benefit was more frequently observed in patients without KRAS mutations or liver metastases. Hyperglycemia was the most common adverse event.
What this means
If your tumor has a PIK3CA mutation and you've exhausted standard chemotherapy options, this combination showed modest activity, especially if you don't have KRAS mutations or liver metastases. However, the survival benefit was limited, so discuss with your oncologist whether this is the right option for you.